Skip to content
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT

Let us tell you more.

We will email you to start the conversation.

Albert Labs announces partnership with drug safety & toxicology experts at the University of CESPU

  • May 12, 2022
  • Interviews

Albert Labs’ Daniel Sanders explains its partnership with the University of CESPU health sciences department in Portugal.

Toxicology is hugely important in pre-clinical drug stages, he says and through the partnership Albert Labs will be establishing good laboratory practices within CESPU’s facility and be able to monitor all aspects of toxicology during pre-clinical trials.

Dr Michael Raymont, chief executive of Albert Labs, spoke to Proactive about the toxicology research for KRN-101. 

KRN-101 is a psilocybin-based drug, and is used as a treatment for cancer-related anxiety. 

Dr Raymont said the company is getting ready to trial this in the Autumn, and investors should know it is making steady progress.

Let us tell you more.

We will email you to start the conversation.

Innovative mental health medicines for patients with unmet needs

  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy

© 2022 Albert Labs. All Rights Reserved

  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Twitter Linkedin Youtube Envelope
CSE:ABRT
FSE: VB50
CSE:ABRT
FSE: VB50

About Albert Labs

We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

If you would like support or more information around making an investment, please contact investing@albertlabs.com

Twitter Linkedin Youtube Envelope

Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.

Twitter
Youtube
Linkedin
Instagram
Envelope
Twitter
Youtube
Linkedin
Instagram
Envelope

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.